Last Updated: April 30, 2026

CLINICAL TRIALS PROFILE FOR CLARINEX D 24 HOUR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Clarinex D 24 Hour

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00636870 ↗ Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine Completed Sanofi Phase 4 2003-02-01 To evaluate the single-dose and steady-state pharmacokinetics of desloratadine and fexofenadine in desloratadine slow metabolizers. To evaluate the safety and tolerability of desloratadine compared to fexofenadine following single and multiple oral doses administered to desloratadine slow metabolizers.
NCT00637585 ↗ Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine Completed Sanofi Phase 4 2002-12-01 To examine the relative potency, onset of action and duration of action of fexofenadine HCl 180 mg (ALLEGRA) and desloratadine 5 mg (CLARINEX) as compared to placebo on skin wheals and flares induced by histamine.
NCT00757562 ↗ Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994) Completed Merck Sharp & Dohme Corp. Phase 3 2002-11-01 This study was conducted to evaluate the safety and tolerance of desloratadine after 5 weeks of repetitive dosing in children ages 2 to 12 years old with allergic hypersensitivity or chronic hives. All of the subjects enrolled in this trial were previously identified in an earlier trial to be poor metabolizers of desloratadine.
NCT00783133 ↗ Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177) Completed Merck Sharp & Dohme Corp. Phase 4 2002-11-01 This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex® or Allegra®. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.
NCT00794248 ↗ Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179) Completed Merck Sharp & Dohme Corp. Phase 4 2002-11-01 This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex® or Allegra®. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Clarinex D 24 Hour

Condition Name

Condition Name for Clarinex D 24 Hour
Intervention Trials
Seasonal Allergic Rhinitis 7
Healthy 5
Perennial Allergic Rhinitis 3
Allergic Rhinitis 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Clarinex D 24 Hour
Intervention Trials
Rhinitis, Allergic 9
Rhinitis 9
Rhinitis, Allergic, Seasonal 7
Rhinitis, Allergic, Perennial 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Clarinex D 24 Hour

Trials by Country

Trials by Country for Clarinex D 24 Hour
Location Trials
United States 8
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Clarinex D 24 Hour
Location Trials
Florida 5
New Jersey 2
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Clarinex D 24 Hour

Clinical Trial Phase

Clinical Trial Phase for Clarinex D 24 Hour
Clinical Trial Phase Trials
Phase 4 9
Phase 3 2
Phase 2 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Clarinex D 24 Hour
Clinical Trial Phase Trials
Completed 18
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Clarinex D 24 Hour

Sponsor Name

Sponsor Name for Clarinex D 24 Hour
Sponsor Trials
Merck Sharp & Dohme Corp. 9
Dr. Reddy's Laboratories Limited 6
Sanofi 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Clarinex D 24 Hour
Sponsor Trials
Industry 19
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clarinex D 24 Hour Market Analysis and Financial Projection

Last updated: April 27, 2026

Clarinex D 24 Hour (Desloratadine + Pseudoephedrine): Clinical-Development Update, Market Status, and Forward Projection

What is Clarinex D 24 Hour and what is the current development stance?

Clarinex D 24 Hour is a fixed-dose combination product that contains:

  • Desloratadine (antihistamine)
  • Pseudoephedrine (decongestant, typically as extended-release)

This product is marketed for allergy symptom relief. In the absence of any clearly identifiable new, registration-enabling clinical program tied to the branded “Clarinex D 24 Hour” label in the public domain, the practical read-through for a market and investment lens is that the product behaves as a mature, marketed asset rather than an active late-stage development target.

Key implication for clinical-trials updates: the public record for the branded combination is dominated by historic approvals and routine postmarketing activities rather than recurrent Phase 2/3 “label-expansion” trials for the branded product itself. Public clinical trial registries generally show limited visibility for branded, fixed-dose, already-approved combination products unless a new indication, new formulation, or a regulatory strategy change is involved.

What clinical trials are visible for the combination in public registries?

Public clinical-trials visibility typically centers on one of three patterns:
1) new chemical entities,
2) new extended-release formulations or bioequivalence work,
3) trials tied to a new indication or regulatory change.

For Clarinex D 24 Hour specifically, the branded combination does not show a consistent pattern in public registries of ongoing Phase 3 programs that would support a near-term “pipeline” projection for the brand in the way investors track for late-stage assets. The more common public evidence for this therapeutic class tends to be:

  • bioequivalence / formulation studies for extended-release pseudoephedrine and antihistamine combinations, and
  • clinical pharmacology studies around dosing, food-effect, and pharmacokinetic bridging.

Is there evidence of a recent label change that would alter market trajectory?

For a branded, mature allergy combination product, label change events usually appear as either:

  • new indication filings (new allergy subtype or population),
  • new dosing instructions (contraindications, age bands),
  • safety communications that constrain market access.

For the public branded product, the clinical and regulatory posture aligns with a stable, established label rather than an active label-expansion strategy. That stability affects how you underwrite near-term growth: the growth driver is typically market share and distribution efficiency, not clinical-driven demand creation.


Market Analysis: Size, Demand Drivers, and Competitive Structure

What is the demand profile for desloratadine + pseudoephedrine 24-hour therapy?

The market for oral “antihistamine plus decongestant” products follows seasonal and co-morbidity demand:

  • seasonal allergic rhinitis is the core indication,
  • upper respiratory symptom overlap (nasal congestion plus sneezing/itching) drives pull-through,
  • patient preference for once-daily extended-release dosing supports adoption when compared with multi-dose alternatives.

Key buying behavior in this segment:

  • patients ask for “allergy” relief with “blocked nose” relief in one product,
  • providers and payers respond to guideline adherence and formulary positioning.

Who competes with Clarinex D 24 Hour?

Competition comes from three buckets:

1) Other antihistamine + decongestant fixed-dose combinations

  • examples in the class include combinations built on second-generation antihistamines and pseudoephedrine or alternative decongestant systems.

2) Standalone antihistamines plus standalone decongestants

  • pharmacy counters and OTC routines allow substitution: a patient buys an antihistamine and a decongestant product separately.

3) Alternative nasal symptom modalities

  • intranasal corticosteroids and antihistamine nasal sprays compete directly for congestion and rhinorrhea.

This structure means the brand’s growth tends to depend on:

  • payer coverage for the brand versus generics,
  • OTC shelf economics,
  • pharmacy loyalty programs and dispensing habits,
  • and patient perceptions around “all-in-one” dosing convenience.

How does generics impact the brand’s economics?

Fixed-dose combinations with established actives are prone to generic competition when patents on specific combinations, formulations, or packaging expire or are not effectively enforced. Once generics enter, brand economics usually shift from pure volume growth to:

  • margin protection via differentiation (perceived efficacy, adherence), and
  • share defense in peak season.

For this therapy category, the expected commercial trajectory is typically:

  • brand share erosion after generic entry,
  • then stabilization where remaining patients prefer established brands and dosing convenience.

Payer and regulatory access: what matters most for this segment?

In allergy OTC and OTC-adjacent structures:

  • formulary placement for switchable items matters for insured channels,
  • safety and labeling constraints on decongestants (pseudoephedrine) influence eligibility,
  • and local regulations on pseudoephedrine sales channels can constrain supply through dispensing controls.

Those forces limit aggressive scaling but do not generally prevent the product from remaining a high-frequency, seasonal SKU.


Forward Projection: What to Expect Over 12 to 36 Months

What drives the base-case trajectory?

For a mature, seasonal, once-daily combination:

  • demand is seasonal and stable in volume terms,
  • price and share are the main swing variables,
  • distribution and substitution drive most variance.

Base case under standard market dynamics:

  • modest unit growth or flat units if the product retains shelf position and seasonal distribution,
  • margin pressure if generic share expands,
  • volatility tied to OTC season intensity (weather patterns) and pharmacy stocking cycles.

What are realistic scenarios?

Without relying on new clinical approvals or pipeline breakthroughs, the most decision-useful scenarios are share and price driven.

Scenario A (share defense / stable pricing)

  • brand holds position during peak seasons,
  • limited incremental competitive displacement,
  • volume roughly matches prior season range.

Scenario B (continued generic share erosion)

  • generics take a larger share of the “allergy with congestion” segment,
  • brand volumes decline gradually,
  • brand marketing shifts toward adherence messaging and “24-hour” compliance positioning.

Scenario C (channel disruption or formulary headwinds ease)

  • improved access, pharmacy preference programs, or payer reversion,
  • volume stabilizes or improves modestly,
  • this scenario depends on commercial terms more than clinical evidence.

Business Implications for R&D and Investment

Where does “clinical trial value” actually show up for this asset class?

For mature combination products, the market impact of clinical trials is rarely “new demand creation.” It tends to show up through:

  • bioequivalence and formulation continuity that prevents supply gaps or regulatory noncompliance,
  • consumer adherence validation for 24-hour dosing,
  • safety communications that protect access rather than expand indications.

If you are evaluating investment upside, the relevant question is not “Is there a new Phase 3 program?” but “Is there a regulatory or formulation event that can protect access or re-anchor patient preference?”

What would change the market outlook materially?

Material change is generally tied to one of:

  • a meaningful new indication that increases patient pool,
  • a new formulation that changes compliance economics or reduces side effects,
  • a major regulatory or safety event that constrains pseudoephedrine access,
  • or a change in patent posture affecting generic entry timing.

Absent those events, the underwriting framework stays anchored in seasonal demand and share competition.


Key Takeaways

  • Clarinex D 24 Hour is a mature, marketed fixed-dose combination of desloratadine plus pseudoephedrine built around 24-hour dosing for allergic rhinitis with nasal congestion.
  • The public clinical-trials footprint for the branded product is not indicative of ongoing late-stage label expansion programs; the observable activity in this class is more consistent with routine formulation or bridging work.
  • Market performance is driven primarily by seasonal demand, pharmacy OTC economics, and generic substitution, not by new clinical efficacy breakthroughs.
  • 12 to 36-month projections are mostly share and pricing dependent, with base-case expectations of stability to gradual erosion under generic competition unless a regulatory or formulation change changes access dynamics.

FAQs

1) Is Clarinex D 24 Hour in clinical development for a new indication?
No public signal indicates active late-stage label expansion tied to the branded fixed-dose combination.

2) What is the primary market need this product addresses?
Oral once-daily symptom relief for allergic rhinitis that includes both histamine symptoms and nasal congestion.

3) What is the biggest risk to brand growth?
Generic entry and substitution that compresses share and margin.

4) What is the biggest upside lever?
Channel or formulary conditions that improve brand retention during peak seasonal periods.

5) Do new clinical trials materially change the demand curve for this asset class?
Typically they protect access or compliance rather than creating a step-change in category demand.


References

[1] U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] ClinicalTrials.gov. Clinical Trials Database. https://clinicaltrials.gov/
[3] World Health Organization. Guidelines for pharmacovigilance and postmarketing safety monitoring. https://www.who.int/teams/regulation-prequalification/effective-medicines/pharmacovigilance

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.